Orgenesis Inc logo

ORGS - Orgenesis Inc Share Price

$4.77 -0.3  -5.0%

Last Trade - 23/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £87.1m
Enterprise Value £19.1m
Revenue £17.1m
Position in Universe 4214th / 6389
Bullish
Bearish
Unlock ORGS Revenue
Momentum
Relative Strength (%)
1m -1.32%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2.97 6.40 10.1 18.7 1.85 33.3 51.7 +62.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Orgenesis Inc revenues increased from $1.6M to $3.6M. Net loss before extraordinary items increased from $13.2M to $34.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Tamir purchase agreement increase from $0K to $19.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ORGS
Graphical History

Revenue

ORGS Revenue Unlock ORGS Revenue

Net Income

ORGS Net Income Unlock ORGS Revenue

Normalised EPS

ORGS Normalised EPS Unlock ORGS Revenue

PE Ratio Range

ORGS PE Ratio Range Unlock ORGS Revenue

Dividend Yield Range

ORGS Dividend Yield Range Unlock ORGS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ORGS EPS Forecasts Unlock ORGS Revenue
Profile Summary

Orgenesis Inc. is a biopharmaceutical company. The Company is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 5, 2008
Public Since May 27, 2011
No. of Shareholders: 108
No. of Employees: 309
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 22,094,470
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ORGS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ORGS
Upcoming Events for ORGS
Frequently Asked Questions for Orgenesis Inc
What is the Orgenesis Inc share price?

As of 23/09/20, shares in Orgenesis Inc are trading at $4.77, giving the company a market capitalisation of £87.1m. This share price information is delayed by 15 minutes.

How has the Orgenesis Inc share price performed this year?

Shares in Orgenesis Inc are currently trading at $4.77 and the price has moved by 19.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Orgenesis Inc price has moved by 8.07% over the past year.

What are the analyst and broker recommendations for Orgenesis Inc?

Of the analysts with advisory recommendations for Orgenesis Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Orgenesis Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Orgenesis Inc next release its financial results?

Orgenesis Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Orgenesis Inc dividend yield?

Orgenesis Inc does not currently pay a dividend.

Does Orgenesis Inc pay a dividend?

Orgenesis Inc does not currently pay a dividend.

When does Orgenesis Inc next pay dividends?

Orgenesis Inc does not currently pay a dividend.

How do I buy Orgenesis Inc shares?

To buy shares in Orgenesis Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Orgenesis Inc?

Shares in Orgenesis Inc are currently trading at $4.77, giving the company a market capitalisation of £87.1m.

Where are Orgenesis Inc shares listed? Where are Orgenesis Inc shares listed?

Here are the trading details for Orgenesis Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ORGS
What kind of share is Orgenesis Inc?

Based on an overall assessment of its quality, value and momentum, Orgenesis Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Orgenesis Inc share price forecast 2020?

Shares in Orgenesis Inc are currently priced at $4.77. At that level they are trading at 79.28% discount to the analyst consensus target price of 0.00.

Analysts covering Orgenesis Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.65 for the next financial year.

How can I tell whether the Orgenesis Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orgenesis Inc. Over the past six months, the relative strength of its shares against the market has been 14.37%. At the current price of $4.77, shares in Orgenesis Inc are trading at -1.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Orgenesis Inc PE Ratio?

We were not able to find PE ratio data for Orgenesis Inc.

Who are the key directors of Orgenesis Inc?

Orgenesis Inc's management team is headed by:

Vered Caplan - CHM
Sarah Ferber - CSO
David Sidransky - DRC
Guy Yachin - DRC
Neil Reithinger - CFO
Yaron Adler - DRC
Mario Philips - DRC
Who are the major shareholders of Orgenesis Inc?

Here are the top five shareholders of Orgenesis Inc based on the size of their shareholding:

Shvartz (Oded) Individual Investor
Percentage owned: 8.29% (1.83m shares)
Image Securities, Ltd. Corporation
Percentage owned: 8.29% (1.83m shares)
Knoll Capital Management, LP Hedge Fund
Percentage owned: 5.96% (1.32m shares)
SFPI-FPIM Investment Advisor
Percentage owned: 4.31% (947k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.31% (952k shares)
Similar to ORGS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.